PF 4634817 / Pfizer - LARVOL DELTA

Identification of Molecular Signatures and Candidate Drugs in Vascular Dementia by Bioinformatics Analyses. (PubMed, Front Mol Neurosci) - "Hub gene-drug interaction analysis found four drugs (maraviroc, cenicriviroc, PF-04634817, and efalizumab) that could be potential drugs for VaD treatment. Together, our results may contribute to understanding the underlying mechanisms in VaD and provide potential targets and drugs for therapeutic intervention."

Journal • Alzheimer's Disease • CNS Disorders • Dementia • Immunology • Inflammation • CD163 • CREB1 • FOXC1 • GATA2 • MIR129 • MIR129-2 • MIR146A • MIR27A • MIR335

Novel Therapies for Kidney Disease in People with Diabetes. (PubMed, J Clin Endocrinol Metab) - "Trials have yielded promising results in the search for new therapies to manage DKD. Sodium-glucose cotransporter-2 inhibitors and incretin-related therapies have demonstrated benefit and were associated with improved cardiovascular outcomes. Mineralocorticoid-receptor antagonists are another class of agents with increasing evidence of benefits."

Journal • Cardiovascular • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Ophthalmology • Renal Disease • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Pfizer pipeline (Pfizer) - PF-04634817 for liver fibrosis discontinued from development

Drug discontinuation • Fibrosis

PF-04634817 renal impairment study (clinicaltrials.gov) - P1, N=26; Sponsor: Pfizer; Recruiting -> Completed.

Trial completion • Renal Disease

Combined inhibition of CCR2 and ACE provides added protection against progression of diabetic nephropathy in Nos3 deficient mice. (PubMed, Am J Physiol Renal Physiol) - "The late intervention (weeks 8-15 after STZ) involved PF-04634817 alone, ACEi (captopril in water 10 mg·kg·day) alone, or combined ACEi + CCR2A. Compared with ACEi alone, combined late intervention with ACEi + CCR2A provided better protection against kidney damage (inflammation, glomerulosclerosis, renal function impairment), but not albuminuria. In conclusion, this study demonstrates that combining CCR2A and ACEi provides broader and superior renal protection than ACEi alone in a model of established diabetic glomerulosclerosis with hypertension."

Journal • Preclinical • Chronic Kidney Disease • Diabetic Nephropathy • Immunology • Metabolic Disorders • Renal Disease